What is the current market size and future outlook for the acute agitation and aggression treatment market?
The acute agitation and aggression treatment market size has grown strongly in recent years. It will grow from $5.72 billion in 2024 to $6.05 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to advances in pharmacology, rise in clinical research, regulatory approvals, rise in prevalence of acute agitation and aggression cases, increased awareness regarding mental health.
The acute agitation and aggression treatment market size is expected to see strong growth in the next few years. It will grow to $7.77 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to growing aging population, growing healthcare infrastructure, rising pharmaceutical industry investment, rise in home-base care, rise in disposable income. Major trends in the forecast period include non-pharmacological interventions, precision medicine, ai and predictive analytics, community-based support, industry collaboration.
Get Your Free Sample of The Global Acute Agitation And Aggression Treatment Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13078&type=smp
How has the acute agitation and aggression treatment market evolved, and what factors have shaped its growth?
The increase in the incidence of dementia is expected to propel the growth of the acute agitation and aggression treatment market going forward. Dementia refers to conditions characterized by impaired memory, cognition, and the capability to manage everyday tasks. A symptom often observed in dementia patients is agitation, manifested through behaviors such as restlessness, repetitive actions, or frequent hand movements. Acute agitation and aggression treatment play a key role in dementia. It reduces the risk of harmful symptoms, improves the patient’s quality of life, and manages the underlying cause of the agitation. For instance, in February 2023, according to the Australian Institute of Health and Welfare, an Australia-based government agency, in 2022, it was projected that about 401,300 Australians have dementia, and this figure is anticipated to be doubled to reach 849,300 in 2058. Therefore, the increase in the incidence of dementia is driving the growth of the acute agitation and aggression treatment market.
What are the major segments of the acute agitation and aggression treatment market?
The acute agitation and aggression treatment market covered in this report is segmented –
1) By Treatment Approach: Behavioral Approaches, Environmental Interventions, Pharmacologic Approaches
2) By Drug Class: Anti-Psychotics, Benzodiazepines, Other Drug Classes
3) By Route of Administration: Oral, Intramuscular, Other Routes of Administrations
4) By Indication: Schizophrenia, Dementia, Bipolar Disorder, Depression, Drug-Induced Agitation And Aggression, Alcohol Withdrawal, Other Indications
5) By End User: Hospitals And Ambulatory Surgical Centers, Psychiatric Care Facilities, Other End Users
Subsegments:
1) By Box Style: Standard Box Action Cameras, Modular Box Action Cameras
2) By Cube Style: Compact Cube Action Cameras, Cube Cameras with Integrated Mounts
3) By Bullet Style: Long, Cylindrical Action Cameras, Mountable Bullet Cameras
4) By Periscope & 360°: 360-Degree Cameras, Periscope Cameras
5) By Other Types: Wearable Action Cameras, Drone Action Cameras, Specialty Action Cameras
Order your report now for swift delivery
Which companies dominate the acute agitation and aggression treatment market?
Major companies operating in the acute agitation and aggression treatment market include Pfizer Inc., Johnson and Johnson Pvt Ltd., F Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, GlaxoSmithKline plc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co Ltd., Mylan NV, Biogen Inc., Bausch Health Companies Inc., UCB SA, Servier Laboratories, Sun Pharmaceutical Industries Ltd., AstraZeneca PLC, Ono Pharmaceutical Co Ltd., Apotex Inc., H Lundbeck A/S, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Neurocrine Biosciences Inc., Aurobindo Pharma Limited, Alkermes plc., Indivior plc., Sunovion Pharmaceuticals Inc., Vanda Pharmaceuticals Inc., and Alexza Pharmaceuticals Inc
How will evolving trends contribute to the growth of the acute agitation and aggression treatment market?
Major companies operating in the acute agitation and aggression treatment market are developing innovative products and getting approved, such as IGALMI (dexmedetomidine), to provide a new treatment option for patients with agitation associated with schizophrenia or bipolar disorder. IGALMI (dexmedetomidine) is a sublingual film used to treat acute agitation associated with schizophrenia or bipolar I or II disorder in adults. For instance, in April 2022, BioXcel Therapeutics Inc., a US-based biopharmaceutical company, received IGALMI (dexmedetomidine) approval from the Food and Drug Administration. It is a quick-acting drug that starts working in a matter of minutes. It is also a short-acting medication, with effects lasting for about 2 hours. It can significantly improve existing therapies for a severe or life-threatening condition.
Which geographic trends are shaping the acute agitation and aggression treatment market, and which region has the highest market share?
North America was the largest region in the acute agitation and aggression treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute agitation and aggression treatment market market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Does The Acute Agitation And Aggression Treatment Market Report 2025 Offer?
The acute agitation and aggression treatment market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Acute agitation and aggression treatment refers to the medical and therapeutic interventions to manage and reduce the sudden onset of restlessness, irritability, and hostility in patients. These agitated and aggressive behaviors can be symptoms of various underlying conditions, including psychiatric disorders, neurological disorders, or substance use or withdrawal effects.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=13078
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
